CD274 and neoplasm: Potential biomarkers for ICI therapy include tumor-intrinsic biomarkers such as TMB, neoantigens, PD-L1 expression, and MSI status; immune-specific biomarkers such as T-cells, Teffector/Tregulatory ratio, tertiary lymphoid structures (TLSs), γ-IFN (gamma interferon), and B cell signatures; and combinatorial biomarkers such as TMB and PD-L1 [77,78].